22300-52-3

Usage

Uses

Used in Pharmaceutical Research:
4,5-Dibromo-2H-1,2,3-triazole is used as a reagent for the discovery of selective small molecular inhibitors of monoacylglycerol acyltransferase 3 (MGAT3). This application is significant because MGAT3 is an enzyme that plays a crucial role in the regulation of lipid metabolism, and its inhibition can have potential therapeutic implications in treating obesity and related metabolic disorders.

Upstream product

• 288-36-8 1 ,2,3-Triazole 
• 288-36-8 1,2,3-triazole 

Downstream Products

• 1192847-36-1 C₁₁H₆Br₂F₃N₃O₂ 
• 1192847-34-9 C₈H₃Br₂FN₄O₂ 
• 1192847-35-0 C₉H₄Br₂N₄O₃ 
• 1192847-32-7 C₉H₄Br₂N₄ 
• 1192847-37-2 C₈H₃Br₃N₄O₂ 
• 1192847-33-8 4,5-dibromo-2-(2-nitrophenyl)-2H-1,2,3-triazole 
• 1248676-21-2 4,5-dibromo-2-ethyl-2H-1,2,3-triazole 
• 1248676-59-6 1-ethyl-4,5-dibromo-1H-1,2,3-triazole 
• 28938-17-2 2-methyl-4,5-dibromo-2H-1,2,3-triazole 
• 25537-64-8 1-methyl-4,5-dibromo-1H-1,2,3-triazole 

Relevant academic research and scientific papers

TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds of Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).

LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

Ruthenium-Catalyzed meta-Selective C?H Nitration of Biologically Important Aryltetrazoles

The first example of tetrazole-directed meta-selective C?H nitration is described. This transformation provided a straightforward approach for the synthesis of biologically important m-nitroaryltetrazoles in moderate to excellent yields with good functional group compatibility. In addition, new metallo-β-lactamase inhibitors were obtained by further transformation of the synthesized m-nitroaryltetrazoles. (Figure presented.).

STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF

The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases, wherein the substituents of the formula (I) are as defined in the description.

Highly selective synthesis of 2-(2H-1,2,3-Triazol-2-yl)benzoic acids

A selective and scalable synthesis of 2-(2H-1,2,3-triazol-2-yl)benzoic acid starting from 1-fluoro-2-nitrobenzene derivatives is presented. The four-step synthesis introduces the triazole at the start via N2-arylation of 4,5-dibromo-2H-1,2,3- triazole. A sequence of consecutive functional group transformations, namely hydrogenation, Sandmeyer iodination, and Grignard carboxylation, provides the target molecules in a reliable and scalable manner. The usefulness of this method is demonstrated by the synthesis of di- or tri(2H-1,2,3-triazol-2-yl)benzene derivatives, which are difficult to produce by other methods.

Highly Selective Synthesis of 2-(2 H-1,2,3-Triazol-2-yl)benzoic Acids

A selective and scalable synthesis of 2-(2H-1,2,3-triazol-2-yl)benzoic acid starting from 1-fluoro-2-nitrobenzene derivatives is presented. The four-step synthesis introduces the triazole at the start via N2-arylation of 4,5-dibromo-2H-1,2,3-triazole. A sequence of consecutive functional group transformations, namely hydrogenation, Sandmeyer iodination, and Grignard carboxylation, provides the target molecules in a reliable and scalable manner. The usefulness of this method is demonstrated by the synthesis of di-or tri(2H-1,2,3-triazol-2-yl)benzene derivatives, which are difficult to produce by other methods.

COMPOUNDS AS MODULATORS OF ROR GAMMA

The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

TRIAZOLE ACC INHIBITORS AND USES THEREOF

The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.